Access cutting-edge lung transplant rejection treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.
Access lung transplant rejection specialists in Stanford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung transplant rejection treatment provided free
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The
Sponsor: Sanofi
Check if you qualify for this lung transplant rejection clinical trial in Stanford, CA
If you're searching for lung transplant rejection treatment options in Stanford, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung transplant rejection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.